EHA 2022 highlights in myeloma and AL amyloidosis

  The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, was held in Vienna, Austria from 9 June to 12 June 2022 in a hybrid format. Myeloma Patients Europe (MPE) attended EHA 2022 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting.  

MPE launches survey on myeloma and AL amyloidosis diagnosis

As part of MPE’s Year of Action, we are excited to announce the launch of the survey on myeloma and AL amyloidosis diagnosis. At MPE, we know that early diagnosis significantly improves the outcomes and quality of life of patients and their experience of healthcare. The survey seeks to understand the perspectives of myeloma and AL amyloidosis patients, as well as haematologists, on the diagnosis challenges. The survey will take approximately 5 minutes to complete and is…

MPE presents its poster on the impact of COVID-19 on the treatment and care of patients with myeloma and AL amyloidosis at IMW 2021

  As the SARS-CoV-2 (COVID-19) pandemic unfolded in 2020, Myeloma Patients Europe (MPE) became aware that the healthcare, treatment, and lives of myeloma and AL amyloidosis patients and their families were impacted by new health policies and national restrictions related to COVID-19.

Register to attend ASH 2021!

  Last March, a number of hematology patient associations, including Myeloma Patients Europe (MPE), coordinated by the Acute Leukemia Advocates Network, wrote a letter to the American Society of Hematology (ASH) that patient advocates need free access to the ASH Annual meeting. The message was heard and non-profit patient advocates (employees and volunteers) from registered patient organisations can now apply to attend the 63rd ASH Annual Meeting in December.

Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in Europe

  The European Commission (EC) has granted marketing authorisation for the expanded use of daratumumab (Darzalex®) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe.